Skip to main content

Table 3 Sensitivity analyses

From: Drug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis

Endpoint

Confidence intervals

Prediction intervals

Only published data

Without STEMI

Only combined DEB+BMS

Excluding progenitor cell stent

DEB exclusively

MACE

0.95 (0.64 to 1.39)

0.95 (0.35 to 2.52)

0.95 (0.64 to 1.39)

0.84 (0.61 to 1.15)

0.84 (0.61 to 1.15)

0.95 (0.64 to 1.39)

1.07 (0.67 to 1.70)

TLR

1.09 (0.71 to 1.68)

1.09 (0.31 to 3.83)

0.97 (0.63 to 1.50)

1.01 (0.68 to 1.51)

1.00 (0.65 to 1.55)

1.20 (0.79 to 1.82)

1.18 (0.70 to 1.99)

Binary restenosis

0.96 (0.48 to 1.93)

0.96 (0.10 to 9.05)

0.96 (0.48 to 1.93)

0.77 (0.40 to 1.48)

0.82 (0.40 to 1.66)

1.18 (0.59 to 2.35)

1.20 (0.48 to 2.96)

MI

1.26 (0.49 to 3.21)

1.26 (0.13 to 11.83)

0.86 (0.40 to 1.85)

1.13 (0.42 to 3.06)

1.18 (0.43 to 3.24)

1.30 (0.46 to 3.65)

1.69 (0.62 to 4.59)

Mortality

0.79 (0.30 to 2.11)

NA

0.58 (0.20 to 1.71)

0.78 (0.29 to 2.15)

0.76 (0.27 to 2.18)

0.88 (0.31 to 2.45)

0.93 (0.32 to 2.71)

ST

1.45 (0.42 to 5.01)

NA

1.45 (0.42 to 5.01)

1.13 (0.29 to 4.40)

1.50 (0.41 to 5.57)

1.52 (0.41 to 5.63)

1.59 (0.40 to 6.36)

  1. BMS, bare metal stent; DEB, drug eluting balloon; MACE, major adverse cardiac events; MI, myocardial infarction; RR, relative risk (and 95% confidence intervals); ST, stent thrombosis; TLR, target lesion revascularization.